Expression of neuropeptide Y is increased in an activated human HSC cell line

• Published in: Scientific reports 2019-07, Vol.9 (1), p.9500-11, Article 9500
• Main Authors: Dai, Wufei, Liu, Yang, Zhang, Yali, Sun, Yufeng, Sun, Changjiang, Zhang, Yu, Lv, Xiufang
• Format: Article
• Language: English
• Subjects: 13/95; 38/35; 38/89; 692/4020/4021; 692/53/2423; 82/80; Adaptor Proteins, Signal Transducing - genetics; Adaptor Proteins, Signal Transducing - metabolism; Arginine - analogs & derivatives; Arginine - pharmacology; Cell Cycle Proteins - genetics; Cell Cycle Proteins - metabolism; Cell Line, Transformed; Cholesterol; Cirrhosis; Fatty acids; Fatty liver; Fibrosis - metabolism; Fibrosis - pathology; Hepatic Stellate Cells - metabolism; Hepatic Stellate Cells - pathology; Hepatocellular carcinoma; Humanities and Social Sciences; Humans; Liver cirrhosis; multidisciplinary; Neuropeptide Y; Neuropeptide Y - genetics; Neuropeptide Y - metabolism; Neuropeptides; Norepinephrine; Phosphorylation; Receptors, Neuropeptide Y - antagonists & inhibitors; Receptors, Neuropeptide Y - genetics; Receptors, Neuropeptide Y - metabolism; Ribosomal Protein S6 Kinases, 70-kDa - genetics; Ribosomal Protein S6 Kinases, 70-kDa - metabolism; Rodents; Science; Science (multidisciplinary); Secretion; Serum levels; Stellate cells; TOR protein; TOR Serine-Threonine Kinases - genetics; TOR Serine-Threonine Kinases - metabolism; Transgenic mice; Triglycerides
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-45932-3

Neuropeptide Y (NPY) is an abundant neuropeptide in the mammalian central and peripheral nervous systems. Transgenic mice overexpressing NPY in noradrenergic neurons have increased level of hepatic triglycerides, fatty acids and cholesterol, which contributed to the development of hepatosteatosis. However, the roles of NPY in the activation of hepatic stellate cells (HSCs) and the underlying mechanisms remain unclear. This study aimed to investigate the expression and secretion of NPY in human immortalized HSC LX-2 cells and the regulatory function of NPY on the fibrogenic response in LX-2 cells, to explore the potential association between NPY and LX-2 activation. The results showed an increase in the expression and secretion of NPY(1–36) in activated LX-2 cells. Both endogenous and exogenous NPY(1–36) induced the phosphorylation of mTOR, p70S6K, and 4EBP1 and promoted the fibrogenic response via NPY Y1 receptor subtype (NPY1R), as these responses were blocked by either an NPY1R antagonist (BIBP3226) or NPY1R knockdown. Moreover, NPY(1–36) serum levels were increased in patients with liver cirrhosis (LC) and hepatocellular carcinoma (HCC) and presented a positive relationship with MELD scores in LC patients. These findings suggest that immortalized HSCs LX-2 have the potential to produce NPY(1–36). High serum levels of NPY(1–36) is correlated with hepatic dysfunction in cirrhotic patients.